Product Images Capecitabine
View Photos of Packaging, Labels & Appearance
- capecitabine-150mg-60tab - capecitabine 150mg 60tab
- capecitabine-500mg-120tab - capecitabine 500mg 120tab
- capecitabine-fig-1 - capecitabine fig 1
- capecitabine-fig-2 - capecitabine fig 2
- capecitabine-fig-3 - capecitabine fig 3
- capecitabine-fig-4 - capecitabine fig 4
- capecitabine-fig-5 - capecitabine fig 5
- capecitabine-str - capecitabine str
Product Label Images
The following 8 images provide visual information about the product associated with Capecitabine NDC 82249-210 by Civicascript Llc, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
capecitabine-150mg-60tab - capecitabine 150mg 60tab
This is a product description for Capecitabine Tablets, USP, with a strength of 150 mg. The pack contains 60 tablets and is for oral use. The usual dosage instructions and important prescribing information are provided in the accompanying leaflet. The tablets should be stored at room temperature, between 20 to 25 degrees Celsius. The product is distributed by Civicascript and the company website is mentioned as ChicaScript.com/Capecitabine. The packaging dimensions are 45mm x 20mm, and the label should have UV varnish for protection. The code number is HPIDRUGS/MNBIOSI105 PL18252.*
capecitabine-500mg-120tab - capecitabine 500mg 120tab
This text is about a medication called Capecitabine. It provides information on the dosing, storage conditions, and the manufacturer (CivicaScript, LLC and Akem Laboratories Ltd.). The medication is presented as film-coated tablets and the recommended storage temperature is between 20° to 25°C (68° to 77°F). The text also suggests referring to additional prescribing information for proper dosage and other guidelines. Additionally, it mentions dispensing in light containers as per USP/NF standards.*
capecitabine-fig-1 - capecitabine fig 1
This appears to be a survival analysis comparing two treatment groups over time (in months) since randomization. The two treatment groups are identified as "5FU+ LEUCOVORIN" and "CAPECITABINE." The table shows the number of subjects at risk for each group at different time points.*
capecitabine-fig-2 - capecitabine fig 2
This document appears to present data related to survival rates for two different treatment groups over a period of 96 months. The first treatment group received 5-FU + Leucovorin, while the second treatment group received Capecitabine. The table shows the number of patients who survived at each time point.*
capecitabine-fig-3 - capecitabine fig 3
This is a comparison chart showing the estimated probability for two different chemotherapy regimens: 5-FU + Leucovorin (Mayo Regimen) and Capecitabine Tablets at a dosage of 1250 mg/sqm twice daily intermittently. The x-axis represents time in days, and the y-axis represents the probability estimates.*
capecitabine-fig-4 - capecitabine fig 4
This text appears to provide information on estimated probabilities for different medications and dosages, including Docetarel, Capecitabine Tablets, and Docetaxel. The document also seems to include a graph or chart showing time (Days) on the x-axis and possibly dosage on the y-axis. The specific details and context of these estimations are not fully clear from this fragment.*
capecitabine-fig-5 - capecitabine fig 5
capecitabine-str - capecitabine str
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
